Renalytix AI enters partnership with Univeristy of Utah Health

The AIM-traded firm said the partnership intended to implement Renalytix AI's in vitro diagnostic platform, ‘KidneyIntelX’, in combination with a range of advanced clinical management solutions to optimise patient care and drive towards improved outcomes system-wide at University of Utah Health, which serves millions of patients in six states.

It said KidneyIntelX was designed for the identification of adults with early-stage chronic kidney disease and diabetes who were at risk for progressive kidney function decline or kidney failure.

Core to the partnership would be the implementation of care navigation and pharmacy programs, behavioural and health economic assessments, and data-driven analytics.

KidneyIntelX would be deployed directly into the electronic health records system at University of Utah Health, enabling access to more than 1,700 clinicians for “seamless” test ordering and patient risk score reporting as part of the standard clinical workflow.

“University of Utah's clinical and translational expertise presents an ideal opportunity to interrupt the devastating and costly effects of progressive chronic kidney disease from its earliest stages to help prevent irreversible late-stage kidney disease and dialysis,” said chief executive officer James McCullough.

“This partnership is enabling Renalytix AI to address a major health problem, help build the life sciences sector in Utah and show the economic value of such a robust public private collaboration.”

At 1056 GMT, shares in Renalytix AI were up 0.23% at 857p.